Scheme S1 -Synthesis of PARPYnD.
Table of Contents

Supplementary Methods
Materials
Chemicals were purchased from Sigma-Aldrich, Fluorochem, Acros Organics, TCI, Alfa Aesar or Fisher Scientific and used without further purification. AzTB and AzRB were synthesized in-house as previously reported. 1 The minimal clickable photocrosslinkable group 5 was synthesized as previously reported. 2 Phthalazinone core 8, AZ9482 and AZ0108 were provided by AstraZeneca. Olaparib was purchased from VWR International. NeutrAvidin agarose resin and PreScission™ Protease were purchased from Thermo Fisher Scientific. Streptavidin magnetic beads were purchased from New England BioLabs. Recombinant GST-PARP6 protein and pcDNA3.1™ mammalian expression vector containing FLAG-PARP6 were provided by AstraZeneca. 6-biotin-17-NAD + was purchased from Bio-Techne Ltd.
Antibodies: anti-PARP1 (SantaCruz, sc-8007), anti-PARP6 (Sigma, HPA026991), anti-HDLBP (Abcam ab109324), anti-GAPDH (Abcam, ab9485), anti-HSP90 (SantaCruz, sc-69703), FLAG-HRP [M2] (Sigma, A8592), NeutrAvidin-HRP (Invitrogen, A2664), anti-mouse-HRP (Advansta, R-05071-500), anti-rabbit-HRP (Advansta, R-05072-500).
Tert-butyl 4-(3-cyanopyridin-2-yl)piperazine-1-carboxylate (5)
2-(Piperazin-1-yl)nicotinonitrile 1 (4.00 g, 21.3 mmol) and di-tert-butyl dicarbonate (4.78 g, 21.9 mmol) were dissolved in CH2Cl2 (60 mL) and cooled to 0 °C. Et3N (5.60 mL, 40.8 mmol) was added drop-wise and the solution was stirred for 4 h at rt. The resulting reaction mixture was quenched with H2O (60 mL) and extracted with CH2Cl2 (3 × 60 mL). The combined organic extracts were washed with H2O (30 mL) and sat. aq. NaCl (30 mL), dried over MgSO4 and concentrated in vacuo. The crude product was purified by flash column chromatography (1:1 EtOAc:n-hexane) to afford 2 as a white crystalline solid (2.70 g, 9.38 mmol, 44%). HRMS (ESI + ) found [M+H] + 289.1661, C15H21N4O2 + requires 289.1665; 1 H NMR (400 MHz, Chloroform-d)  ppm 8.35 (dd, J = 4.9, 2.0 Hz, 1H), 7.79 (dd, J = 7.6, 2.1 Hz, 1H), 6.79 (dd, J = 7.5, 4.7 Hz, 1H), 3.69 -3.65 (m, 4H), 3.61 -3.57 (m, 4H), 1.48 (s, 9H).
Tert-butyl 4-(5-bromo-3-cyanopyridin-2-yl)piperazine-1-carboxylate (6)
Tert-butyl 4-(3-cyanopyridin-2-yl)piperazine-1-carboxylate 2 (2.70 g, 9.38 mmol) was dissolved in DMF (10 mL) and the solution cooled to 0 °C. N-bromosuccinimide (2.01 g, 11.3 mmol) was added and the reaction stirred at rt for 3 h. The reaction was quenched with H2O (5 mL) and concentrated in vacuo. The crude residue was dissolved in EtOAc (30 mL) and sat. aq. NaHCO3 (15 mL) and aq. LiCl (5% (w/v), 15 mL) were added. The mixture was extracted with EtOAc (3 × 30 mL) and the combined organic layers were washed successively with sat. aq. NaHCO3 (15 mL), aq. LiCl (5% (w/v), 15 mL) and sat. aq. NaCl (30 mL). The organics were dried over Na2SO4 and concentrated in vacuo to yield 3 as a pale yellow solid (3.18 
Tert-butyl 4-(5-amino-3-cyanopyridin-2-yl)piperazine-1-carboxylate (7)
Tert-butyl 4-(5-bromo-3-cyanopyridin-2-yl)piperazine-1-carboxylate 3 (1.00 g, 2.72 mmol), CuI (103 mg, 0.542 mmol), L-proline (563 mg, 4.08 mmol), K2CO3 (563 mg, 4.08 mmol) and a stirrer bar were sealed inside a microwave vial which was flushed with Ar. DMSO (2.5 mL) was added and stirred at rt for 5 min. NH4OH (30% (w/w), 0.520 mL, 4.08 mmol) was added and the reaction mixture stirred at 90 °C for 12 h. After cooling, the reaction was quenched with H2O (50 mL) and extracted with Et2O (3 × 50 mL). The combined organic layers were washed with sat. aq. NaCl (50 mL), dried over MgSO4, filtered and concentrated in vacuo. The 
Tert-butyl 4-(5-(3-(3-(but-3-yn-1-yl)-3H-diazirin-3-yl)propanamido)-3-cyanopyridin-2yl)piperazine-1-carboxylate (9)
DIPEA (110 L, 0.631 mmol), tert-butyl 4-(5-amino-3-cyanopyridin-2-yl)piperazine-1carboxylate 4 (64 mg, 0.211 mmol), and 3-(3-(but-3-yn-1-yl)-3H-diazirin-3-yl)propanoic acid 5 (35 mg, 0.211 mmol) were dissolved in DMF (2 mL). Propylphosphonic acid cyclic anhydride (50% (v/v) in EtOAc, 249 L, 4.19 mmol) was added and the reaction stirred at rt for 1 h. The reaction mixture was diluted with sat. aq. NaHCO3 (5 mL) and extracted with EtOAc (3 × 5 mL). The combined organic layers were washed with sat. aq. NaHCO3 (5 mL) and aq. LiCl (5% (w/v), 2 × 5 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude residue was purified by flash column chromatography (1:7 acetone:CH2Cl2) to yield 6 as a brown oil (219 mg, 0.448 mmol, 75% 
3-(3-(But-3-yn-1-yl)-3H-diazirin-3-yl)-N-(5-cyano-6-(piperazin-1-yl)pyridin-3yl)propanamide (10)
piperazine-1-carboxylate 6 (37 mg, 0.0819 mmol) was dissolved in CH2Cl2 (3 mL) . Nmethylmorpholine (0.460 mL, 0.419 mmol) and trimethylsilyl iodide (0.330 mL, 0.231 mmol) were added and stirred under Ar at rt for 24 h. The reaction mixture was quenched with sat. aq. NaHCO3 (5 mL) and the aqueous layer extracted with CH2Cl2 (3 × 5 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to yield 7 as a crude brown oil (28 mg, 0.0798 mmol, 96%) that was taken forward without further purification. 
3-(3-(But-3-yn-1-yl)-3H-diazirin-3-yl)-N-(5-cyano-6-(4-(3-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)pyridin-3-yl)propanamide (PARPYnD 3)
DIPEA (51 L, 0.293 mmol), 3-(3-(but-3-yn-1-yl)-3H-diazirin-3-yl)-N-(5-cyano-6-(piperazin-1yl)pyridin-3-yl)propanamide 7 (28 mg, 0.0798 mmol), and 3-((4-oxo-3,4-dihydrophthalazin-1yl)methyl)benzoic acid 8 (22 mg, 0.0798 mmol) were dissolved in DMF (500 L). Propylphosphonic acid cyclic anhydride (50% (v/v) in EtOAc, 95 L, 0.293 mmol) was added and the reaction stirred at rt for 30 min. The reaction mixture was diluted with sat. aq. NaHCO3 (5 mL) and extracted with EtOAc (3 × 5 mL). The combined organic layers were washed with sat. aq. NaHCO3 (5 mL) and aq. LiCl (5% (w/v), 2 × 5 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude residue was purified by preparative reverse phase LC-MS 
Tissue Culture
All cell culturing was carried out in a sterile tissue culture cabinet sprayed with 70% (v/v) EtOH before and after use. All cell lines were cultured at 37 °C in a 5% CO2 incubator. MDA-MB-468 cells were cultured in Dubecco's Modified Eagle Mediumlow glucose (DMEM) supplemented with 10% (v/v) Fetal Bovine Serum (FBS). Cell harvesting was achieved by washing with Dubecco's PBS and treatment with 0.25% (w/v) Trypsin-EDTA. After 5 min incubation at 37 °C, the trypsin was quenched with DMEM to the appropriate volume for passage and aliquoted into the appropriate number of cell culture plates. Mycoplasma tests were carried out monthly. Passage number was limited to 20-25 and stocks of early passages were frozen at -150 °C containing ~10 6 cells in 1 mL FBS containing 10% (v/v) DMSO.
Multipolar Spindle Assay
This was performed as described previously. 3 Briefly, HeLa cells were plated in 96-well plates at 7,000 cells per well and incubated at 37 °C overnight. The cells were treated with compounds in a dose-dependent manner from 0 to 11 M for 48 h. The cells were fixed by 4% (v/v) formaldehyde at room temperature for 10 min and followed by ice-cold methanol fixation for another 10 min. After washing with PBS four times, the cells were blocked in blocking buffer for 1 h at room temperature. The cells were labelled with primary antibodies, 1:2000 dilution of anti-cyclin B antibody (Thermo Fisher) and 1:4000 dilution of anti-pericentrin antibody (Abcam), for 16 h at 4 °C. After washing with PBS four times, the cells were labelled with secondary antibodies, 1:200 Alexa Fluor 488 anti-rabbit antibody and Alexa Fluor 594 anti-mouse antibody, for 1 h at room temperature. After washing with PBS twice, the nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI) for 10 min at room temperature. The cells were washed twice with PBS and then applied to image acquisition by ImageXpress Micro High Content Screening System (Molecular Devices). The data were analyzed by MetaXpress and accessed by AcuityXpress (Molecular Devices). The 16 fields in each well were acquired by ImageXpress Micro. The cyclin B was labelled for scoring the mitotic cells and pericentrin was labelled for scoring the centrosome number in each mitotic cell. Value output was taken as % mitotic cells with greater than 2 centrosomes.
In vitro PARP fluorescence anisotropy binding assays Dilution of various PARP proteins and fluorescence anisotropy probe
Recombinant full length 6HIS-tagged PARP1 protein was diluted to 6 nM with 50 mM Tris pH 8, 0.001% (v/v) Triton X-100, 10 mM MgCl2, 150 mM NaCl and incubated for four hours with an equivalent volume of 2 nM fluorescent probe diluted with 50 mM Tris pH 8, 0.001% (v/v) Triton X-100, 10 mM MgCl2, 150 mM NaCl. The final DMSO concentration of the probe was kept below 1% (v/v).
Recombinant full length PARP2 protein was diluted to 6 nM with 50 mM Tris pH 8, 0.001% (v/v) Triton X-100, 10 mM MgCl2, 150 mM NaCl and incubated for four hours with an equivalent volume of 2 nM fluorescent probe diluted with 50 mM Tris pH 8, 0.001% (v/v) Triton X-100, 10 mM MgCl2, 150 mM NaCl. The final DMSO concentration of the probe was kept below 1% (v/v).
Recombinant PARP5a binding domain was diluted to 160 nM with 50 mM Tris pH 8, 0.001% (v/v) Triton X-100, 10 mM MgCl2, 150 mM NaCl and incubated for four hours with an equivalent volume of 6 nM fluorescent probe diluted with 50 mM Tris pH 8, 0.001% (v/v) Triton X-100, 10 mM MgCl2, 150 mM NaCl. The final DMSO concentration of the probe was kept below 1% (v/v).
Recombinant full length GST-tagged PARP6 protein was diluted to 160 nM with 50 mM Tris pH 8, 0.001% (v/v) Triton X-100, 10 mM MgCl2, 150 mM NaCl and incubated for four hours with an equivalent volume of 6 nM fluorescent probe diluted with 50 mM Tris pH 8, 0.001% (v/v) Triton X-100, 10 mM MgCl2, 150 mM NaCl. The final DMSO concentration of the probe was kept below 1% (v/v).
Experimental protocol
Fluorescence anisotropy of the probe when bound to the proteins was measured using a BMG Pherastar FS © in the presence of test compounds or solvent control and the effect on anisotropy determined. % inhibition values for different test compound concentrations were calculated and fitted to a four parameter logistic plot in order to determine the IC50 value.
Cell Viability Assay (MTS)
MDA-MB-468 cells were seeded 24 h before treatment in a sterile treated 96-well plate at a density of 8000 cells per well to a final volume of 50 L in DMEM. PBS (100 L) was added to the outer wells. DMEM (50 L) containing 0.2% (v/v) DMSO (positive control, final amount 0.1% (v/v) on plate) or puromycin (negative control, 8 mM, final concentration 4 mM on plate), or different concentrations of compound in DMSO to be tested (final 0.1% (v/v) DMSO, prepared by serial dilution, dilution factor 3, starting from 3 M, final plate concentration starting from 1.5 M) were added to the cells in triplicate. 72 h later, a solution of MTS assay powder (3.28 mM in PBS 1×, Promega) and phenazine methosulfate (3 mM in H2O, Sigma-Aldrich) was prepared (20:1) and 20 L was added to each well. Absorbance was measured 4 times per well at 490 nm and the average absorbance taken. The average of the negative control was subtracted from every value and viability was calculated as a percentage relative to the positive control. EC50 values were calculated by fitting data to the IC50 function using GraphPad Prism 5 software.
Probe labelling assays
Probe incubation was carried out in sterile treated 6-well plates (2 mL working volume) or 10 cm dishes (7 mL working volume). All compound treatments were performed with a preprepared 1000× stock of the desired concentration in DMSO and added directly to the relevant plate/well with mixing. Irradiation was performed with an in-house designed and built UV LED box (C. Saunders) with a monochromatic wavelength of 365 nm. Optimal probe incubation times were determined previously through irradiation and lysis at various time points and selection of the earliest saturating time point.
For each experiment, the plates/dishes were pre-seeded with MDA-MB-468 cells and the experiment carried out when cells had achieved 90-100% confluency. DMEM was replaced and the plates/dishes were incubated at 37 °C for 15 min. For competition experiments only, the relevant plates/wells were first treated with DMSO vehicle (0.1% (v/v)) or varying concentrations of parent compound in DMSO as indicated and incubated at 37 °C for 1 h before treating with probe. For all probe labelling experiments, competition or otherwise, the plates/dishes were treated with either DMSO vehicle (0.1% (v/v)) or varying concentrations of probe as required by the experiment and incubated at 37 °C for 3 h.
For photocrosslinking, the following was performed 1 plate/3 dishes at a time out of the incubator. Each plate/dish had media replaced and was irradiated with UV light for 30 s (365 nm) and placed on ice while irradiation of other samples was performed.
The cells were relieved of media, washed twice with PBS, then lysed with lysis buffer (70 L (6-well plates), 300 L (10 cm dishes); 1% (v/v) Triton X-100, 1% (w/v) sodium dodecyl sulfate (SDS), EDTA-free complete protease inhibitor cocktail (1×, Roche) in PBS) on ice for 10 min. The lysates were scraped and transferred to corresponding Lo-Bind Eppendorfs. Each lysate was probe sonicated (20% amplitude, 20 s (2 s pulse, 3 s rest)) to shear the nuclear DNA. Protein concentration was determined using the DC Protein Assay (Bio-Rad) in a 96-well plate as per manufacturer's instructions.
Click reaction
The desired amount of lysed protein from each sample was made up to 0.5-2 mg mL -1 with PBS to a total volume of ≤300 L. The following "click mixture" was prepared separately, preparing 6 L for every 100 L of lysate: The click mixture was vortexed and incubated at rt for 2 min before 6 L of the mixture was added to every 100 L of lysate. The reaction mixtures were shaken at rt for 1 h before being quenched with EDTA (500 mM in H2O) to a final concentration of 5 mM.
A table-top centrifuge was pre-chilled to 4 °C. Proteins were precipitated by adding H2O (1 vol), MeOH (2 vol) and CHCl3 (0.5 vol), vortexing briefly then centrifuging at 17,000 × g for 5 min. The CHCl3 and H2O/MeOH layers were discarded and the middle layer of protein pellet was retained. The pellet was washed with MeOH (300 L), sonicated to break up the pellet then stored at -80 °C for at least 20 min. The proteins were pelleted by centrifugation at 10,000-17000 × g for 5-10 min or until a compact pellet was formed. The MeOH was decanted and the pellet air-dried for 5 min. The pellet was resuspended by completely dissolving in 1% (w/v) SDS in PBS (to 5 mg mL -1 protein) before being made up to 1 mg mL -1 protein with PBS.
In-gel fluorescence 10-or 15-well SDS-polyacrylamide gels with a 12% resolving gel and 4% stacking gel were used for all gel electrophoresis experiments and were prepared using the following recipe (makes 2 gels): Figure S1 . PARP in vitro binding assays. Dose-response curves for PARPYnD tested in fluorescence anisotropy competition assay with various recombinant PARP enzymes. N, number of biological replicatesdata displayed ±SEM of these replicates, fit to 4 parameter dose-response function. PARP1 IC50 = 0.038 M, PARP2 IC50 = 0.006 M, PARP6 IC50 = 0.230 M. Raw data can be found in Extended Data 1. Figure S4 . Photocrosslinking dose-response assay up to 10 M. MDA-MB-468 cells were treated with up to 10 M PARPYnD for 3 h, irradiated (365 nm), lysed and ligated to AzTB (Figure S3 ). Samples were enriched on magnetic streptavidin beads and both lysate (input) and pull down were analyzed by in-gel fluorescence and immunoblot. PARP6 cannot be detected in the enriched fraction over any concentration of PARPYnD up to 10 M, over 10 times the reported IC50. Figure S6 . Crosslinking with cleavage experiment. In-gel fluorescence of PARPYnD labelled lysate with PARP6 ±cleavage with PreScission™ Protease. GST tag was found to have no effect on binding and/or labelling. Cleaving the tag off after labelling (lanes 4-6) shows that the 71 kDa PARP6 portion of the protein is labelled (*). Cleaving the tag off before labelling (lanes 7-9) shows that the GST tag does not bias the recombinant protein towards compound binding. 
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